CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine today announced plans to increase the company’s operational capacity at a new facility in San Diego, California. The site will primarily be used for additional research and development laboratories to accommodate expanded capabilities for the Cambridge-based, cancer genomics insights company.
Foundation Medicine’s new location will include more than 63,000 square feet of mixed-use space optimized for both laboratory operations and research and development. The new office will consolidate the company’s two San Diego locations under one roof in Torrey Pines, the center of the city’s life science cluster.
The new laboratory space, projected to be complete next year, will help to expand testing capacity of the company’s recently FDA-approved FoundationOne Liquid CDx liquid biopsy test. Additionally, with Foundation Medicine’s acquisition of Lexent Bio in June, the new space will allow for increased research and development of low-pass whole genome sequencing and DNA methylation analysis.
“This state-of-the-art facility provides the opportunity to further expand our R&D and laboratory operations and supports our focus on advancing personalized medicine for patients,” said Foundation Medicine’s Chief Scientific Officer Priti Hegde, Ph.D. “The San Diego region is home to more than 1,200 life sciences companies—we’re excited to embed ourselves in this burgeoning community, deepen our local partnerships and add this high-quality lab space to expand into new projects.”
Foundation Medicine’s labs in Cambridge; Research Triangle Park, North Carolina; and Penzberg, Germany will continue to analyze individual patients’ genomic profiles, using the company’s portfolio of genomic tests, to identify the molecular alterations in a patient’s cancer and help physicians match them with relevant personalized treatment approaches, including targeted therapies, immunotherapies and clinical trial options.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
Source: Foundation Medicine